Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells

BACKGROUND: Triple-negative breast cancer (TNBC) has aggressive progression with poor prognosis and ineffective treatments. Selumetinib is an allosteric, ATP-noncompetitive inhibitor of MEK1/2, which has benn known as effective antineoplastic drugs for several malignant tumors. We hypothesized that...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yan, Lin, Shuchen, Tseng, Kuo-Fu, Han, Kun, Wang, Yaling, Gan, Zhi-hua, Min, Da-liu, Hu, Hai-yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073736/
https://www.ncbi.nlm.nih.gov/pubmed/27769200
http://dx.doi.org/10.1186/s12885-016-2773-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073736/
https://www.ncbi.nlm.nih.gov/pubmed/27769200
http://dx.doi.org/10.1186/s12885-016-2773-4

Ejemplares similares